{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:30:52Z","timestamp":1791307852321,"version":"4.3.1"},"reference-count":0,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2007]]},"DOI":"10.1615\/critrevimmunol.v27.i4.10","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T03:13:17Z","timestamp":1342235597000},"page":"291-302","source":"Crossref","is-referenced-by-count":36,"title":["PART II. Toxins as Therapeutic AgentsAlpha-Cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature Leading to Its Development for This Application"],"prefix":"10.1615","volume":"27","author":[{"given":"Paul F.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","container-title":["Critical Reviews\u2122 in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dl.begellhouse.com\/download\/article\/53705ae3475f70b7\/CRI2704 %5B291-302%5D.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T13:24:11Z","timestamp":1550237051000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,485bc4905e12ea7e,53705ae3475f70b7.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.v27.i4.10","relation":{},"ISSN":["2162-6472"],"issn-type":[{"value":"2162-6472","type":"print"}],"subject":[],"published":{"date-parts":[[2007]]}}}